George J Hanna

List of Publications by Year
in descending order

62	3,538	159585 30	133252 59
papers	citations	h-index	g-index

63	63	63	3551
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial. Clinical Infectious Diseases, 2021, 73, 33-42.	5.8	38
2	Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial. Lancet HIV,the, 2021, 8, e324-e333.	4.7	24
3	Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virusâ€“1: An Integrated Safety Analysis. Clinical Infectious Diseases, 2020, 70, 1336-1343.	5.8	6
4	Once-daily Doravirine in Human Immunodeficiency Virus Type 1â€“Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis. Clinical Infectious Diseases, 2020, 70, 1344-1352.	5.8	9
5	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. Lancet HIV,the, 2020, 7, e16-e26.	4.7	53
6	Efficacy and safety of elbasvir/grazoprevir in treatmentâ€naive Chinese adults with hepatitis C virus infection: A randomized trial. JGH Open, 2020, 4, 1065-1073.	1.6	2
7	Efficacy and safety of a twoâ€drug directâ€acting antiviral agent regimen ruzasvir 180Âmg and uprifosbuvir 450Âmg for 12Âweeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. Journal of Viral Hepatitis, 2019, 26, 1127-1138.	2.0	10
8	Recommendations for analytical antiretroviral treatment interruptions in HIV research trialsâ€”report of a consensus meeting. Lancet HIV,the, 2019, 6, e259-e268.	4.7	139
9	Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1597-1603.	2.8	11
10	Efficacy and safety of ruzasvir 60Âmg and uprifosbuvir 450Âmg for 12Âweeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection. Journal of Viral Hepatitis, 2019, 26, 675-684.	2.0	6
11	Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, e47-e49.	2.1	18
12	Evaluation of Neural Tube Defects (NTDs) After Exposure to Raltegravir During Pregnancy. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 247-250.	2.1	13
13	Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 463-472.	2.1	57
14	Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virusâ€“1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clinical Infectious Diseases, 2019, 68, 535-544.	5.8	122
15	Elbasvir/Grazoprevir in Black Adults With Hepatitis C Virus Infection: A Pooled Analysis of Phase 2/3 clinical Trials. American Journal of Gastroenterology, 2018, 113, 863-871.	0.4	2
16	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV,the, 2018, 5, e211-e220.	4.7	108
17	Neuropathic Pain Medication Use Does Not Alter Outcomes of Spinal Cord Stimulation for Lower Extremity Pain. Neuromodulation, 2018, 21, 106-113.	0.8	9
18	Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asiaâ€“Pacific region and Russia: Final results from the randomized Câ€CORAL study. Journal of Gastroenterology and Hepatology (Australia), 2018, 34, 12-21.	2.8	20

#	Article	IF	Citations
19	Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 589-598.	2.1	20
20	Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 299-307.	2.1	34
21	Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Antiretroviral-Experienced Subjects: Week 48 Analysis of AI438011, a Phase IIb, Randomized Controlled Trial. Antiviral Therapy, 2017, 22, 215-223.	1.0	26
22	Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529. Antimicrobial Agents and Chemotherapy, 2016, 60, 2782-2789.	3.2	18
23	Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial. Lancet HIV,the, 2016, 3, e13-e22.	4.7	11
24	Pharmacokinetic Interactions between BMS-626529, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug BMS-663068, and Ritonavir or Ritonavir-Boosted Atazanavir in Healthy Subjects. Antimicrobial Agents and Chemotherapy, 2015, 59, 3816-3822.	3.2	18
25	Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. Lancet HIV,the, 2015, 2, e427-e437.	4.7	53
26	Human Immunodeficiency Virus (HIV)-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 48 Subgroup Analysis. Open Forum Infectious Diseases, 2015, 2, .	0.9	1
27	540HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis. Open Forum Infectious Diseases, 2014, 1, S22-S23.	0.9	1
28	Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery. Drug Discovery Today, 2014, 19, 1288-1293.	6.4	13
29	Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068. Journal of Antimicrobial Chemotherapy, 2014, 69, 573-581.	3.0	56
30	Randomized Placebo-Controlled Study of the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of 10-Day Monotherapy With BMS-986001, a Novel HIV NRTI, in Treatment-Experienced HIV-1â€“Infected Subjects. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 346-354.	2.1	12
31	Activity of the HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068, against CD4-Independent Viruses and HIV-1 Envelopes Resistant to Other Entry Inhibitors. Antimicrobial Agents and Chemotherapy, 2013, 57, 4172-4180.	3.2	67
32	In VitroCross-Resistance Profile of Nucleoside Reverse Transcriptase Inhibitor (NRTI) BMS-986001 against Known NRTI Resistance Mutations. Antimicrobial Agents and Chemotherapy, 2013, 57, 5500-5508.	3.2	21
33	Prediction of Virological Response and Assessment of Resistance Emergence to the HIV-1 Attachment Inhibitor BMS-626529 During 8-Day Monotherapy With Its Prodrug BMS-663068. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 7-15.	2.1	38
34	Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects. Journal of Infectious Diseases, 2012, 206, 1002-1011.	4.0	92
35	In VitroAntiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068. Antimicrobial Agents and Chemotherapy, 2012, 56, 3498-3507.	3.2	118
36	Adherence to Chronic Hepatitis B Treatment Guideline Recommendations for Laboratory Monitoring of Patients Who Are Not Receiving Antiviral Treatment. Journal of General Internal Medicine, 2011, 26, 239-244.	2.6	37

#	Article	IF	Citations
37	In VivoPatterns of Resistance to the HIV Attachment Inhibitor BMS-488043. Antimicrobial Agents and Chemotherapy, 2011, 55, 729-737.	3.2	47
38	Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects. Antimicrobial Agents and Chemotherapy, 2011, 55, 722-728.	3.2	59
39	Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3879-3884.	7.1	577
40	A 96â€Week Comparison of Lopinavirâ€Ritonavir Combination Therapy Followed by Lopinavirâ€Ritonavir Monotherapy versus Efavirenz Combination Therapy. Journal of Infectious Diseases, 2008, 198, 234-240.	4.0	102
41	Effects of Acidâ€Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavirâ€Boosted Atazanavir. Journal of Clinical Pharmacology, 2008, 48, 553-562.	2.0	42
42	Seven-Year Efficacy of a Lopinavir/Ritonavir-Based Regimen in Antiretroviralâ€"NaÃ¯ve HIV-1-Infected Patients. HIV Clinical Trials, 2008, 9, 1-10.	2.0	57
43	â€œWhite Coat Complianceâ€•Limits the Reliability of Therapeutic Drug Monitoring in HIV-1â€"Infected Patients. HIV Clinical Trials, 2008, 9, 238-246.	2.0	111
44	ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia. PLoS Pathogens, 2007, 3, e46.	4.7	296
45	Decreased Adherence to Antiretroviral Therapy Observed prior to Transient Human Immunodeficiency Virus Type 1 Viremia. Journal of Infectious Diseases, 2007, 196, 1773-1778.	4.0	72
46	The Tablet Formulation of Lopinavir/Ritonavir Provides Similar Bioavailability to the Soft-Gelatin Capsule Formulation With Less Pharmacokinetic Variability and Diminished Food Effect. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 401-410.	2.1	157
47	Predictive Genotypic Algorithm for Virologic Response to Lopinavir-Ritonavir in Protease Inhibitor-Experienced Patients. Antimicrobial Agents and Chemotherapy, 2007, 51, 3067-3074.	3.2	34
48	Evidence of Ongoing Immune Reconstitution in Subjects with Sustained Viral Suppression following 6 Years of Lopinavir-Ritonavir Treatment. Clinical Infectious Diseases, 2007, 44, 749-754.	5.8	38
49	Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen. Journal of Antimicrobial Chemotherapy, 2007, 59, 957-963.	3.0	13
50	In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 2 with Decreased Susceptibility to Lopinavir. Antimicrobial Agents and Chemotherapy, 2007, 51, 3075-3080.	3.2	26
51	A Lopinavir/Ritonavir-Based Once-Daily Regimen Results in Better Compliance and Is Non-inferior to a Twice-Daily Regimen Through 96 Weeks. AIDS Research and Human Retroviruses, 2007, 23, 1505-1514.	1.1	60
52	Substitution with Lopinavir/Ritonavir Improves Patient-Reported Outcomes Including Quality of Life in Patients Who Were Intolerant to Their Antiretroviral Therapy. HIV Clinical Trials, 2006, 7, 291-308.	2.0	11
53	A Once-Daily Lopinavir/Ritonavir-Based Regimen Provides Noninferior Antiviral Activity Compared With a Twice-Daily Regimen. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 153-160.	2.1	106
54	Drugâ€Selected Resistance Mutations and Nonâ€B Subtypes in Antiretroviralâ€Naive Adults with Established Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 2003, 188, 986-991.	4.0	30

#	Article	IF	Citations
55	HIV-1 genotypic and phenotypic resistance. Clinics in Laboratory Medicine, 2002, 22, 637-649.	1.4	4
56	Testing for HIV-1 drug resistance. Molecular Diagnosis and Therapy, 2001, 6, 253-263.	1.1	3
57	Human Immunodeficiency Virus Type 1 Hypersusceptibility to Amprenavir In Vitro Can Be Associated with Virus Load Response to Treatment In Vivo. Clinical Infectious Diseases, 2001, 33, 2075-2077.	5.8	17
58	Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy. Journal of Virology, 2001, 75, 4999-5008.	3.4	225
59	Clinical Use of Genotypic and Phenotypic Drug Resistance Testing to Monitor Antiretroviral Chemotherapy. Clinical Infectious Diseases, 2001, 32, 774-782.	5.8	111
60	Comparative Analysis of HIV Type 1 Genotypic Resistance across Antiretroviral Trial Treatment Regimens. AIDS Research and Human Retroviruses, 2000, 16, 1325-1336.	1.1	10
61	Comparison of Sequencing by Hybridization and Cycle Sequencing for Genotyping of Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Journal of Clinical Microbiology, 2000, 38, 2715-2721.	3.9	31
62	Antiretroviral drug resistance in HIV-1. Current Infectious Disease Reports, 1999, 1, 289-297.	3.0	16